two
decad
sinc
initi
discoveri
dna
vaccin
technolog
come
long
way
unfortun
appli
human
subject
inadequ
immunogen
still
biggest
challeng
practic
dna
vaccin
use
mani
differ
strategi
test
preclin
model
address
problem
includ
novel
plasmid
vector
codon
optim
enhanc
antigen
express
new
gene
transfect
system
electropor
increas
deliveri
effici
protein
live
viru
vector
boost
regimen
maximis
immun
stimul
formul
dna
vaccin
tradit
molecular
adjuv
better
understand
mechan
action
dna
vaccin
also
enabl
better
use
intrins
host
respons
dna
improv
vaccin
immunogen
review
summar
recent
advanc
dna
vaccin
technolog
relat
intracellular
event
might
impact
futur
direct
dna
vaccin
develop
unlik
convent
proteinbas
vaccin
dna
vaccin
base
bacteri
plasmid
encod
vaccin
antigen
driven
effici
eukaryot
promot
like
protein
vaccin
dna
vaccin
deliv
varieti
differ
rout
includ
intramuscular
subcutan
mucos
transderm
deliveri
howev
unlik
protein
antigen
dna
vaccin
effect
must
gain
entri
cytoplasm
cell
inject
site
order
induc
antigen
express
vivo
therebi
enabl
antigen
present
major
histocompat
molecul
mhc
tcell
recognit
dna
vaccin
prove
success
varieti
anim
model
prevent
treat
infecti
diseas
cancer
autoimmun
allergi
dna
vaccin
mani
advantag
tradit
vaccin
vaccin
design
straightforward
gener
requir
onestep
clone
plasmid
vector
therebi
reduc
cost
product
time
furthermor
vivo
express
antigen
gene
driven
eukaryot
promot
endogen
posttransl
modif
result
nativ
protein
structur
ensur
appropri
process
immun
present
safeti
aspect
clone
synthesi
nucleic
acid
rather
purifi
protein
pathogen
avoid
need
use
pathogen
microorgan
vaccin
manufactur
recombin
dna
technolog
allow
almost
kind
molecular
manipul
plasmid
dna
includ
vitro
mutat
enabl
rapid
redesign
antigen
pathogen
influenza
exhibit
constant
antigen
drift
plasmid
dna
good
safeti
record
human
common
side
effect
mild
inflamm
inject
site
plasmid
dna
stabl
room
temperatur
avoid
need
cold
chain
transport
dna
vaccin
enabl
express
antigen
present
mhc
class
class
ii
complex
therebi
enabl
stimul
cell
alreadi
sever
veterinari
dna
vaccin
approv
use
includ
fish
infecti
haematopoiet
necrosi
viru
dog
melanoma
swine
growth
hormon
releas
hormon
hors
west
nile
viru
human
applic
technolog
lag
larg
due
suboptim
immunogen
compar
tradit
vaccin
approach
address
obstacl
larg
number
differ
strategi
enhanc
dna
vaccin
immunogen
test
includ
vector
design
improv
antigen
codon
optim
use
tradit
adjuv
molecular
adjuv
electropor
coexpress
molecular
adjuv
primeboost
strategi
review
specif
focus
promot
select
dna
vaccin
vector
potenti
shortcom
codon
optim
potenti
new
insight
omic
studi
rnai
technolog
molecular
adjuv
target
strategi
technolog
deliveri
dna
vaccin
although
mani
describ
advanc
far
test
preclin
model
increas
number
advanc
stage
human
clinic
trial
test
first
proofofconcept
dna
vaccin
test
involv
inject
rna
dna
vector
express
chloramphenicol
acetyltransferas
luciferas
betagalactosidas
mous
skelet
muscl
express
report
gene
vivo
readili
detect
last
two
month
subsequ
gene
gun
studi
show
dnacoat
gold
microprojectil
propel
mous
skin
highli
effici
induc
antibodi
respons
express
antigen
final
shown
inject
plasmid
express
influenza
nucleoprotein
quadricep
balbc
mice
could
induc
cytotox
lymphocyt
immun
mice
protect
challeng
heterolog
influenza
viru
strain
similar
studi
chicken
also
demonstr
protect
influenza
viru
challeng
two
dose
dna
vaccin
although
earli
studi
confirm
potenti
use
nucleic
acid
vaccin
mani
practic
question
still
need
address
first
safeti
plasmid
dna
risk
would
integr
chromosom
induc
activ
oncogen
mutat
tumour
suppressor
gene
increas
chromosom
instabl
subsequ
studi
confirm
dna
vaccin
extrem
low
probabl
human
genom
integr
level
lower
even
spontan
mutat
anoth
import
question
dna
vaccin
given
extrem
low
level
express
abl
induc
immun
respons
compar
short
halflif
inject
protein
antigen
plasmid
dna
provid
tissu
express
antigen
much
longer
period
time
therebi
potenti
prime
immun
system
better
regard
antigen
present
three
possibl
mechan
propos
plasmid
dna
internalis
express
somat
cell
eg
myocyt
present
mhc
class
complex
cell
profession
antigen
present
cell
apc
eg
dendrit
cell
attract
inject
site
transfect
plasmid
dna
express
antigen
present
cell
mhc
class
ii
complex
phagocytosi
plasmidtransfect
somat
cell
profession
apc
result
crossprim
present
antigen
cell
muscl
cell
abl
present
antigen
mhc
class
ii
need
induc
helper
cell
direct
indirect
present
profession
apc
like
rout
intrins
element
plasmid
dna
also
activ
innat
immun
respons
therebi
enhanc
adapt
immun
respons
express
antigen
innat
immun
system
use
patternrecognit
receptor
prr
sens
invas
pathogen
induc
downstream
product
type
interferon
proinflammatori
cytokin
mous
human
tolllik
cytosol
prr
bind
dna
sequenc
contain
unmethyl
cytosineguanin
cpg
motif
lead
activ
signal
pathway
cpg
motif
rare
mammalian
genom
gener
methyl
wherea
bacteria
unmethyl
cpg
motif
common
inclus
builtin
cpg
motif
dna
vaccin
backbon
act
activ
transfect
abil
dna
vaccin
activ
suggest
import
prime
primeboost
context
although
cpg
motif
play
import
role
vaccin
action
knockout
mice
show
essenti
dna
vaccin
work
suggest
cytosol
dna
sensor
may
also
contribut
dna
vaccin
immunogen
one
prr
cyclicgmpamp
cgamp
synthas
cga
recognit
dsdna
induc
cgamp
activ
stimul
interferon
gene
sting
anoth
dna
prr
dai
also
activ
sting
induc
type
interferon
express
downstream
cga
dai
import
enhanc
dna
vaccin
action
anoth
import
cytosol
dna
sensor
induc
inflammasom
activ
inflammatori
cytokin
product
recent
studi
show
humor
cellular
antigenspecif
adapt
respons
dna
vaccin
significantli
reduc
mice
helicas
protein
rigi
sens
cytosol
nucleic
acid
may
contribut
dna
vaccin
action
potenti
dna
sensor
includ
dnapk
henc
prr
downstream
signal
pathway
may
provid
valuabl
mean
enhanc
dna
vaccin
action
figur
tradit
vaccin
research
small
rodent
laboratori
anim
princip
use
dna
vaccin
research
exampl
queri
human
host
dnavaxdb
databas
collect
verifi
dna
vaccin
studi
data
return
record
queri
mous
return
current
databas
total
record
verifi
dna
vaccin
studi
includ
anim
model
clearli
label
although
studi
cite
review
undertaken
mous
model
rather
human
critic
import
understand
mechan
dna
vaccin
work
help
improv
vector
design
deliveri
method
use
test
adjuv
valuat
safeti
issu
vaccin
success
small
anim
model
guarante
translat
human
studi
remain
import
part
vaccin
develop
pipelin
increas
number
advanc
preclin
model
advanc
human
clinic
trial
shown
figur
retriev
total
number
record
dna
vaccin
lead
human
clinic
trial
databas
clinicaltrialsgov
half
entri
indic
rel
infanc
human
dna
vaccin
research
eightytwo
percent
regist
dna
vaccin
trial
list
phase
phase
one
trial
list
phase
look
distribut
diseas
dna
vaccin
current
use
target
direct
virus
like
hiv
influenza
hepat
target
cancer
consist
need
new
type
vaccin
virus
diseas
well
address
use
tradit
vaccin
approach
reassuringli
date
major
safeti
problem
emerg
human
dna
vaccin
trial
codon
usag
pathogen
often
differ
mammalian
speci
henc
codon
optim
gener
requir
achiev
effici
mammalian
express
pathogen
protein
earli
studi
mous
model
show
success
codon
optim
result
enhanc
cell
respons
neutral
antibodi
titr
support
recent
studi
current
differ
academ
commerci
algorithm
codon
optim
avail
assist
dna
vaccin
develop
howev
codon
optim
alway
posit
correl
dna
vaccin
efficaci
exampl
malaria
dna
vaccin
studi
mice
show
nativ
nucleic
acid
sequenc
provid
robust
tcell
respons
protect
p
yoelii
sporozoit
challeng
anoth
murin
studi
use
codonoptim
plasmid
express
schistosoma
mansoni
protein
show
increas
immun
protect
mansoni
challeng
discrep
suggest
assumpt
codon
optim
may
alway
hold
true
mani
studi
shown
rarecodon
may
alway
speedlimit
step
frequent
use
codon
guarante
increas
protein
product
furthermor
synonym
codon
could
potenti
chang
protein
conform
function
recent
review
mauro
et
al
furthermor
origin
pathogen
sequenc
may
provid
better
adjuv
effect
prr
interact
codon
optim
sequenc
therefor
best
origin
codonoptim
sequenc
alway
compar
earli
phase
develop
new
dna
vaccin
dna
vaccin
gene
express
normal
driven
polymeras
ii
type
promot
endogen
mammalian
pol
ii
promot
strong
virusderiv
promot
cytomegaloviru
cmv
promot
eg
pci
pcmv
earli
studi
show
cmv
immedi
earli
enhancerpromot
strongest
activ
cell
type
thu
wide
use
dna
vaccin
design
studi
use
env
dna
vaccin
shown
stronger
promot
induc
higher
protein
express
immun
respons
viral
promot
effici
drive
antigen
express
alway
correl
vaccin
efficaci
effect
may
explain
viral
promot
sensit
inhibit
inflammatori
cytokin
nonvir
promot
mhc
class
ii
promot
shown
mice
overcom
issu
henc
cmv
promot
given
abil
drive
high
level
protein
express
remain
first
choic
dna
vaccin
altern
promot
may
result
better
vaccin
outcom
plasmid
vector
use
dna
vaccin
contain
bacteri
element
replic
signal
select
marker
propag
e
coli
element
pose
safeti
issu
result
poor
antigen
express
exampl
autoimmun
issu
occur
ampicillin
select
marker
express
vector
replac
kanamycin
select
marker
remov
redund
vector
sequenc
also
make
possibl
clone
larger
dna
vaccin
fragment
use
sucros
select
system
tradit
select
marker
replac
sucros
select
construct
design
incorpor
base
pair
enhanc
cmv
promot
increas
extrachromosom
transgen
express
human
tlymphotrop
viru
type
htlvi
r
region
cmv
promot
increas
translat
effici
use
system
increas
neutral
antibodi
titer
dna
vaccin
achiev
rabbit
complet
remov
bacteri
element
minicircl
dna
mcdna
technolog
develop
use
sitespecif
recombin
base
para
resolvas
gener
mcdna
use
induc
minicircleassembl
enzym
integras
iscei
home
endonucleas
mcdna
technolog
success
use
gene
therapi
experi
mous
model
recent
studi
shown
minicircl
dna
superior
plasmid
dna
elicit
antigenspecif
tcell
respons
anoth
studi
show
modifi
novel
miniintron
plasmid
mip
system
robustli
express
vivo
vitro
may
therebi
serv
better
vaccin
backbon
anoth
studi
combin
electropor
deliveri
along
minicircl
dna
technolog
result
enhanc
immunogen
gag
dna
vaccin
mice
vaccin
adjuv
use
increas
immunogen
otherwis
weakli
immunogen
antigen
vaccin
adjuv
function
seri
mechan
includ
activ
innat
immun
system
format
depot
effici
antigen
deliveri
induct
differ
chemokin
express
enhanc
antigen
uptak
present
profession
apc
upregul
costimulatori
surfac
molecul
adjuv
shown
enhanc
immunogen
dna
vaccin
alum
wide
use
vaccin
adjuv
sinc
thought
work
via
induct
phagocyt
cell
death
result
immun
danger
signal
addit
alum
adjuv
dna
vaccin
encod
hbsag
increas
antibodi
respons
mice
guinea
pig
nonhuman
primat
similarli
formul
toxoplasma
gondii
dna
vaccin
alum
adjuv
lead
increas
surviv
balbc
mice
altern
alum
polysaccharid
adjuv
base
deltainulin
particl
use
dna
primeprotein
boost
vaccin
strategi
significantli
increas
humor
cellular
respons
antienvrespons
mice
approach
dna
vaccin
use
liposom
spheric
vesicl
compos
lipid
bilay
includ
phospholipid
cholesterol
liposom
entrap
bind
plasmid
dna
facilit
dna
entri
cell
penetr
lipid
bilay
cell
membran
although
use
liposom
intramuscular
antigen
deliveri
need
improv
overcom
injectionsit
reactogen
remain
promis
candid
mucos
vaccin
recent
studi
mice
show
oral
vaccin
cation
liposomeencapsul
influenza
viru
gene
induc
humor
cellular
immun
respons
protect
mice
respiratori
infect
liposom
also
shown
effect
intranas
dna
vaccin
howev
whole
tradit
adjuv
best
modest
effect
dna
vaccin
immunogen
lead
attempt
develop
potent
molecular
adjuv
approach
mani
vaccin
plasmidencod
immunestimulatori
molecul
includ
variou
cytokin
gene
prr
ligand
test
genet
adjuv
genet
molecular
adjuv
take
advantag
recombin
dna
technolog
allow
encod
plasmid
vaccin
coadminist
plasmid
tolllik
receptor
tlr
class
membranebound
prr
play
key
role
innat
immun
system
far
relat
human
tlr
gene
identifi
recogn
dsrna
ssdna
respect
ligand
shown
act
molecular
adjuv
poli
c
classic
ligand
poli
c
adjuv
enhanc
induc
ctl
immun
decreas
tumour
burden
mice
given
dna
cancer
vaccin
poli
c
similarli
enhanc
respons
dna
vaccin
combin
cpgpoli
c
adjuv
enhanc
immunogen
mice
dna
vaccin
eastern
equin
enceph
viru
similarli
ligand
cpg
success
use
enhanc
immunogen
dna
vaccin
rigilik
receptor
import
intracellular
protein
sens
doubl
strand
rna
rigi
ligand
enhanc
humor
immun
respons
influenza
dna
vaccin
similarli
sendai
virusderiv
ligand
rigi
enhanc
immunogen
influenza
dna
vaccin
tlr
rigilik
receptor
rlr
inflammasom
stingdepend
cytosol
dna
sensor
ligand
initi
cell
differenti
ligand
cytosol
dna
sensor
dai
also
shown
effici
molecular
adjuv
dna
cancer
vaccin
cytokin
natur
produc
small
protein
critic
immun
cell
signal
cytokineencod
plasmid
prepar
along
antigenexpress
plasmid
local
express
cytokin
inject
site
avoid
potenti
toxic
system
administ
cytokin
interleukin
il
induc
prolifer
nk
cell
extens
studi
genet
adjuv
fusion
construct
mycoplasma
pneumonia
gene
carboxi
termin
region
result
enhanc
vaccin
respons
mice
therapeut
vaccin
chronic
myeloid
leukemia
express
bcrablpir
togeth
also
show
enhanc
immun
respons
anoth
proinflammatori
cytokin
secret
dc
monocyt
express
plasmid
shown
enhanc
immun
respons
bicistron
plasmid
express
yersinia
pesti
epitop
increas
mucos
iga
serum
igg
protect
mice
challeng
express
plasmid
also
use
clinic
trial
weakli
immunogen
hepat
b
dna
vaccin
recent
studi
show
genet
adjuv
enhanc
hepat
c
dna
vaccin
immunogen
stimul
product
studi
toxoplasma
gondii
dna
vaccin
show
immun
respons
surviv
rate
increas
inclus
genet
adjuv
compar
hivsiv
dna
vaccin
also
success
dna
prime
protein
boost
studi
evalu
pennvaxb
dna
vaccin
mixtur
express
plasmid
encod
clade
b
env
gag
pol
adjuv
dna
plasmid
show
vaccin
safe
administr
pennvaxb
plu
electropor
signific
dosespar
effect
provid
superior
tcell
immunogen
gmcsf
known
recruit
apc
immun
site
promot
dc
matur
success
use
dna
vaccin
includ
pseudorabi
viru
gbencod
siv
encod
denv
serotyp
prme
encod
vaccin
howev
recent
studi
show
coadministr
gmcsf
plasmid
deleteri
effect
caus
suppress
dna
vaccin
dengu
viru
type
type
fail
improv
respons
induc
hcv
vaccin
furthermor
excess
gmcsf
expand
myeloid
suppressor
cell
suppress
adapt
immun
respons
notabl
preclin
macaqu
studi
gmcsf
express
recombin
siv
mav
vaccin
enhanc
protect
therefor
use
molecular
adjuv
finetun
gmcsf
express
level
must
also
consid
cytokin
induc
nk
cell
prolifer
synergist
effect
seen
dna
vaccin
toxoplasma
gondii
infect
sequenti
administr
gene
enhanc
cell
memori
dna
vaccin
foot
mouth
diseas
henc
combin
multipl
cytokin
dna
vaccin
formul
sequenti
vaccin
cytokin
may
enhanc
vaccin
efficaci
easi
clone
cytokin
gene
make
promis
candid
dna
vaccin
adjuv
moder
durabl
express
inject
site
plasmidexpress
cytokin
help
overcom
problem
short
halflif
mani
cytokin
minim
risk
system
cytokin
storm
restrict
cytokin
express
inject
site
although
human
data
use
cytokineencod
plasmid
vaccin
adjuv
limit
appear
promis
direct
finetun
immun
respons
dna
vaccin
past
ten
year
understand
immun
signal
pathway
greatli
progress
make
possibl
test
signal
molecul
vaccin
adjuv
signal
molecul
trif
success
test
genet
adjuv
dna
vaccin
similarli
cotransfect
enhanc
better
ctl
respons
dna
vaccin
base
plasmid
shown
enhanc
dnavaccineinduc
cell
respons
hiv
rigi
like
dsrna
receptor
enhanc
dna
vaccin
influenza
viru
infect
chicken
recent
studi
show
plasmid
express
interferon
regulatori
transcript
factor
irf
enhanc
ctl
respons
tat
vaccin
wherea
effect
observ
plasmid
master
innat
immun
regul
recent
studi
show
coadministr
plasmid
express
subunit
rela
enhanc
dna
vaccin
immunogen
tcell
transcript
factor
tbet
effect
drive
respons
dnabas
tuberculosi
vaccin
dna
bind
cellular
receptor
activ
innat
immun
pathway
recent
studi
found
short
noncod
dna
fragment
improv
electroporationmedi
gene
transfer
vivo
immun
potenc
hbv
vaccin
shrna
sirna
molecular
adjuv
rna
interfer
rnai
posttranscript
gene
silenc
process
trigger
doublestrand
short
hairpin
rna
shrna
structur
sinc
discoveri
rnai
mainli
use
research
tool
loss
function
studi
target
gene
rnai
use
downregul
gene
suppress
dna
vaccin
action
exampl
use
shrna
knock
caspas
cell
death
mediat
upregul
dna
vaccin
increas
plasmid
gene
express
tcell
antibodi
respons
similarli
deplet
rnai
critic
suppress
regul
cell
prolifer
increas
efficaci
cancer
vaccin
knockdown
receptor
also
shown
enhanc
vaccin
potenc
furthermor
blockad
ligand
rnai
augment
dcmediat
cell
respons
antivir
immun
hbv
transgen
mice
recent
cancer
vaccin
studi
combin
sirna
cpg
show
increas
protect
immun
b
cell
lymphoma
anoth
cancer
therapeut
vaccin
show
gmcsf
combin
shrna
knockdown
furin
augment
vaccin
efficaci
knockdown
apobec
express
rnai
also
enhanc
dna
vaccin
immunogen
thu
use
rnai
target
gene
limit
plasmid
express
might
power
new
strategi
dna
vaccin
enhanc
especi
tumour
vaccin
safeti
approach
still
need
fulli
evalu
anim
studi
dna
vaccin
mainli
transfect
muscl
cell
result
poor
antigen
present
due
lack
costimul
instead
gene
express
target
profession
apc
enhanc
vaccin
action
one
strategi
direct
transfect
dc
convent
approach
use
ex
vivoengin
dc
vaccin
enrich
dc
blood
transfect
dna
given
back
patient
one
recent
mous
studi
show
dc
transfect
plasmid
migrat
lymph
node
readminist
mice
given
high
cost
dc
vaccin
approach
like
use
therapeut
cancer
vaccin
recent
studi
improv
efficaci
plasmid
dna
ad
target
protein
polym
peptid
liu
et
al
translat
albumin
hitchhik
approach
dna
vaccin
use
lipophil
albuminbind
tail
target
cargo
dc
skin
deliveri
dna
load
polym
form
nanoparticl
use
target
langerhan
cell
barrier
direct
target
dna
dc
overcom
incub
dna
vaccin
small
peptid
deriv
rabi
viru
glycoprotein
fuse
protamin
residu
addit
direct
target
dna
dc
anoth
strategi
coexpress
dctarget
molecul
dna
vaccin
construct
mani
target
approach
success
mous
model
utilis
wide
rang
target
molecul
includ
fire
receptor
cire
ctype
lectin
receptor
synthet
mhc
class
iitarget
peptid
subcellular
target
anoth
strategi
enhanc
plasmidencod
antigen
process
andor
present
use
target
endoplasm
reticulum
lamp
target
lysosom
greatli
enhanc
dna
vaccin
efficaci
target
autophagi
pathway
enhanc
efficaci
tuberculosi
dna
vaccin
similarli
short
polypeptid
herp
simplex
viru
induc
antigen
aggreg
autophagosom
degrad
enhanc
tcellrespons
coexpress
chicken
ovalbumin
plasmid
patrex
express
aggreg
domain
induc
intracellular
protein
aggreg
autophagi
caspas
activ
translat
increas
respons
dna
vaccin
encod
plasmodium
yoelii
merozoit
surfac
protein
fusion
padr
mhc
class
ii
epitop
cancer
dna
vaccin
also
abl
induc
stronger
antigenspecif
respons
target
dna
vaccin
specif
cell
subcellular
compart
greatli
increas
antigen
process
present
promot
desir
immun
respons
minim
system
toxic
therebi
promis
area
molecular
adjuv
develop
among
differ
way
target
dc
skin
target
method
intraderm
inject
microneedl
may
superior
tradit
intramuscular
subcutan
inject
rout
discuss
section
vaccin
deliveri
devic
develop
nextgener
sequenc
microarray
high
throughput
proteom
approach
provid
opportun
identifi
addit
potenti
molecular
adjuv
dna
vaccin
one
recent
proteom
studi
screen
protein
interact
plasmid
dna
found
human
serum
amyloid
p
sap
inhibit
plasmid
transfect
enhanc
clearanc
sap
may
contribut
low
efficaci
dna
vaccin
human
suppress
effect
much
weaker
speci
therefor
might
possibl
includ
shrna
sap
molecular
adjuv
human
dna
vaccin
system
biolog
approach
also
use
analyz
molecular
signatur
correl
posit
immun
respons
exampl
camkiv
kinas
express
level
day
neg
correl
subsequ
influenza
antibodi
titer
provid
exampl
applic
system
biolog
identifi
biomark
predict
vaccin
effect
identifi
molecul
serv
potenti
new
candid
molecular
adjuv
immunogen
dna
vaccin
limit
human
primeboost
approach
like
dna
primeprotein
boost
dna
primevir
vector
boost
eg
use
adenoviru
even
protein
primedna
boost
provid
opportun
develop
effect
human
dna
vaccin
regimen
previou
studi
use
dnaprotein
dnaadvector
approach
hiv
vaccin
recent
studi
use
heterolog
primeboost
approach
show
enhanc
immunogen
therapeut
vaccin
hepat
c
viru
higher
protect
recombin
base
surrog
challeng
model
anoth
studi
show
dna
primeadenoviru
boost
malaria
vaccin
encod
p
falciparum
csp
induc
cellmedi
immun
steril
protect
similar
studi
also
show
greatli
enhanc
immunogen
peptid
primedna
boost
bcg
primedna
boost
interv
prime
boost
also
import
best
vaccin
efficaci
underli
mechan
effect
primeboost
strategi
still
remain
poorli
understood
hypothes
lower
antigen
express
dna
vaccin
may
preferenti
prime
thelper
cell
respons
humor
respons
subsequ
boost
protein
viralvector
boost
overcom
main
issu
low
dna
vaccin
immunogen
effici
deliveri
plasmid
prefer
tissu
cell
critic
research
area
case
convent
protein
vaccin
dna
vaccin
administr
mani
differ
method
includ
convent
syring
inject
gene
gun
electropor
ep
li
nanoparticl
microneedl
liposom
base
anim
studi
ep
combin
primeboost
strategi
may
give
highest
immunogen
howev
even
though
clinic
trial
ep
success
undertaken
shown
dosespar
effect
ep
guarante
increas
vaccin
immunogen
may
practic
mani
human
vaccin
henc
simpler
effici
method
still
need
dna
vaccin
deliveri
potenti
candid
includ
needlefre
skin
deliveri
pulmonari
deliveri
needlefre
skin
gene
deliveri
system
use
highpressur
fine
stream
target
differ
skin
depth
deliv
dna
abl
transfect
langerhan
cell
skin
commerci
devic
biojector
pharmajet
shown
abl
deliv
dna
vaccin
anim
model
human
trial
recent
studi
use
rabbit
model
show
influenza
dna
vaccin
deliv
needlefre
idal
vaccin
elicit
similar
antibodi
respons
intraderm
electropor
anoth
clinic
trial
use
biojector
deliv
dna
vaccin
good
toler
prime
cell
product
antibodi
respons
boost
consid
safeti
lowcost
eas
use
abil
deliv
drycoat
plasmid
needlefre
inject
devic
show
much
promis
dna
vaccin
deliveri
intranas
intrapulmonari
deliveri
dna
vaccin
addit
altern
although
number
human
studi
administr
rout
limit
theori
pulmonari
vaccin
expos
deliv
dna
express
antigen
larg
surfac
epitheli
immun
cell
avoid
need
needl
inject
recent
studi
show
cationcomplex
plasmid
dna
vaccin
appli
topic
murin
pulmonari
mucosa
induc
mucos
system
immun
respons
model
furthermor
complex
pei
pulmonari
dna
vaccin
induc
signific
influenza
protect
anoth
studi
show
pulmonari
dna
immun
mediat
protect
antivir
immun
enhanc
airway
cell
respons
biggest
challeng
pulmonari
deliveri
need
special
deliveri
method
convent
jet
ultrason
nebul
fail
deliv
larg
intact
biomolecul
like
plasmid
dna
lung
high
shear
cavit
stress
present
nebul
howev
recent
progress
area
deliveri
method
may
chang
surfac
acoust
wave
nebul
shown
effici
deliv
aerosol
plasmid
dna
vaccin
rat
sheep
induct
system
mucos
antibodi
respons
progress
overcom
low
immunogen
problem
dna
vaccin
steadili
made
recent
advanc
summar
tabl
along
better
understand
immun
pathway
vaccin
action
larg
array
immun
receptor
signal
molecul
cytokin
transcript
factor
process
test
dna
vaccin
adjuv
like
least
turn
potent
adjuv
although
need
care
assess
human
safeti
toler
abil
present
nativ
conform
immunogen
abl
prime
humor
cellular
immun
respons
hallmark
dna
vaccin
consid
suitabl
li
chicken
embryo
fibroblast
requir
codon
optim
product
nake
dna
dna
vaccin
benefit
abl
express
antigen
nativ
conform
insid
cell
therebi
induc
cell
respons
current
human
dna
vaccin
trial
ongo
complet
anim
human
trial
data
show
good
toler
safeti
dna
vaccin
codon
optim
strong
viral
promot
alway
enhanc
dna
vaccin
immunogen
minicircl
dna
miniintron
plasmid
system
promis
bacteri
elementfre
dna
vaccin
product
molecular
adjuv
includ
plasmidencod
cytokin
signal
molecul
rna
knockdown
strategi
use
enhanc
dna
vaccin
immunogen
needlefre
skin
deliveri
pulmonari
deliveri
method
may
promis
direct
futur
use
